UK markets closed

NewAmsterdam Pharma Company N.V. (NAMS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
19.64-0.20 (-1.01%)
As of 02:17PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close19.84
Open19.59
Bid19.55 x 200
Ask19.94 x 100
Day's range19.01 - 20.21
52-week range5.63 - 26.35
Volume38,754
Avg. volume189,438
Market cap1.767B
Beta (5Y monthly)0.08
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings

    -- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- NAARDEN, the Netherlands and MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company d

  • Globe Newswire

    NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

    -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first patients in TANDEM, pivotal Phase 3 trial evaluating fixed-dose combination of obicetrapib and ezetimibe; topline data expected in 1Q 2025 -- -- Company to host R&D event on May 16, 2024, beginning at 9:00 a.m. ET in New York City – -- Strong financial position; ending the quarter with $

  • GlobeNewswire

    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s